Novo Nordisk A/S NOV.DE · Stock Open Novo Nordisk A/S in new tab
Novo Nordisk A/S Analysis (NOV.DE)
Is Novo Nordisk A/S a good investment? Novo Nordisk A/S (NOV.DE) is currently trading at 33.98 EUR.
In terms of valuation, the stock trades at a P/E ratio of 9.46. This relatively low multiple may signal that Novo Nordisk A/S is undervalued compared to historical market norms.
Earnings Schedule: Novo Nordisk A/S is expected to release its next earnings report on Nov. 4, 2026.
For income investors, Novo Nordisk A/S pays a dividend yield of 4.76%. With a payout ratio of 45%, the dividend appears sustainable.
Investor FAQ
Does Novo Nordisk A/S pay a dividend?
Yes, it pays an annual dividend of 11.70 EUR (4.76% yield).
What asset class is Novo Nordisk A/S?
Novo Nordisk A/S is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 4, 2026. The company currently has a trailing EPS of 3.51.
Company Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Year | Total Dividends |
|---|---|
| ▸2027 |
1.76 EUR
|
| Aug. 18, 2027 (estimated) | 0.5611 |
| March 22, 2027 (estimated) | 1.1954 |
| ▸2026 |
1.56 EUR
|
| Aug. 18, 2026 | 0.5012 |
| March 31, 2026 | 1.0625 |
| ▸2025 |
1.56 EUR
|
| Aug. 19, 2025 | 0.5012 |
| April 1, 2025 | 1.0558 |
| ▸2024 |
1.32 EUR
|
| Aug. 19, 2024 | 0.4678 |
| March 26, 2024 | 0.8554 |
| ▸2023 |
2.84 EUR
|
| Aug. 22, 2023 | 0.8046 |
| Aug. 22, 2023 | 0.4009 |
| March 28, 2023 | 0.5446 |
| March 28, 2023 | 1.0933 |
| ▸2022 |
2.24 EUR
|
| Aug. 16, 2022 | 0.5710 |
| Aug. 16, 2022 | 0.2840 |
| March 29, 2022 | 0.9269 |
| March 29, 2022 | 0.4611 |
| ▸2021 |
1.88 EUR
|
| Aug. 18, 2021 | 0.4703 |
| Aug. 18, 2021 | 0.2339 |
| March 30, 2021 | 0.7862 |
| March 30, 2021 | 0.3909 |
| ▸2020 |
1.73 EUR
|
| Aug. 18, 2020 | 0.4361 |
| Aug. 18, 2020 | 0.2172 |
| March 31, 2020 | 0.7161 |
| March 31, 2020 | 0.3575 |
| ▸2019 |
1.64 EUR
|
| Aug. 20, 2019 | 0.2005 |
| Aug. 20, 2019 | 0.4019 |
| March 26, 2019 | 0.3441 |
| March 26, 2019 | 0.6897 |
| ▸2018 |
1.58 EUR
|
| Aug. 21, 2018 | 0.4020 |
| Aug. 21, 2018 | 0.2005 |
| March 27, 2018 | 0.6507 |
| March 27, 2018 | 0.3241 |
| ▸2017 |
1.53 EUR
|
| Aug. 22, 2017 | 0.4031 |
| Aug. 22, 2017 | 0.2005 |
| March 24, 2017 | 0.6179 |
| March 24, 2017 | 0.3074 |
| ▸2016 |
1.89 EUR
|
| Aug. 12, 2016 | 0.4030 |
| Aug. 12, 2016 | 0.2005 |
| March 21, 2016 | 0.4276 |
| March 21, 2016 | 0.8578 |
| ▸2015 |
1.00 EUR
|
| March 20, 2015 | 0.6704 |
| March 20, 2015 | 0.3341 |
| ▸2014 |
0.90 EUR
|
| March 21, 2014 | 0.3007 |
| March 21, 2014 | 0.6024 |
| ▸2013 |
2.65 EUR
|
| March 21, 2013 | 2.4133 |
| March 21, 2013 | 0.2406 |
| ▸2012 |
2.07 EUR
|
| March 22, 2012 | 0.1871 |
| March 22, 2012 | 1.8814 |
| ▸2011 |
1.47 EUR
|
| March 24, 2011 | 0.1336 |
| March 24, 2011 | 1.3399 |
| ▸2010 |
1.11 EUR
|
| March 25, 2010 | 0.1002 |
| March 25, 2010 | 1.0071 |
| ▸2009 |
0.88 EUR
|
| March 19, 2009 | 0.0802 |
| March 19, 2009 | 0.8045 |
| ▸2008 |
0.66 EUR
|
| March 13, 2008 | 0.6028 |
| March 13, 2008 | 0.0601 |
| ▸2007 |
1.03 EUR
|
| March 8, 2007 | 0.0935 |
| March 8, 2007 | 0.9388 |
| ▸2006 |
0.88 EUR
|
| March 9, 2006 | 0.8035 |
| March 9, 2006 | 0.0802 |
| ▸2005 |
0.71 EUR
|
| March 10, 2005 | 0.6428 |
| March 10, 2005 | 0.0641 |
| ▸2004 |
0.65 EUR
|
| March 17, 2004 | 0.0588 |
| March 17, 2004 | 0.5892 |
| ▸2003 |
0.53 EUR
|
| March 26, 2003 | 0.4821 |
| March 26, 2003 | 0.0481 |
| ▸2002 |
0.49 EUR
|
| March 13, 2002 | 0.4486 |
| March 13, 2002 | 0.0448 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Novo Nordisk A/S | Aug 18, 2026 | Paid | 0.501188 EUR |
| Novo Nordisk A/S | Mar 31, 2026 | Paid | 1.062518 EUR |
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 2, 2014 | 5:1 |
| Sept. 13, 2023 | 2:1 |
Community Discussion